IL33 and Carcinoma, Lewis Lung: Interestingly, the antitumor activity of recombinant IL-33 (rIL-33) in the Lewis lung carcinoma (LLC) model was totally abrogated in the Sema4A knock-out (KO) mouse, indicating the relevance of the activation of DCs in the IL-33-mediated antitumor activity (22).